Literature DB >> 21951951

Acute myeloid leukemia of donor origin after allogeneic stem cell transplantation from a sibling who harbors germline XPD and XRCC3 homozygous polymorphisms.

Hilda Rachel Diamond1, Maria Helena Ornellas, Alberto Orfao, Bernadete E Gomes, Mércia M Campos, Teresa S Fernandez, Roberto I da Silva, Gilda Alves, Claudia Lage, Dayse A da Silva, Arthur Moellmann-Coelho, Geydson S da Cruz, Luis Fernando Bouzas, Eliana Abdelhay.   

Abstract

A 54-year-old woman was diagnosed with infiltrative ductal breast carcinoma. Two years after treatment, the patient developed an acute myeloid leukemia (AML) which harbored del(11q23) in 8% of the blast cells. The patient was submitted for allogeneic stem cell transplantation (aSCT) from her HLA-compatible sister. Ten months after transplantation, she relapsed with an AML with basophilic maturation characterized by CD45(low) CD33(high), CD117⁺, CD13(-/+), HLA Dr(high), CD123(high), and CD203c⁺ blast cells lacking expression of CD7, CD10, CD34, CD15, CD14, CD56, CD36, CD64, and cytoplasmic tryptase. Karyotype analysis showed the emergence of a new clone with t(2;14) and FISH analysis indicated the presence of MLL gene rearrangement consistent with del(11q23). Interestingly, AML blast cell DNA tested with microsatellite markers showed the same pattern as the donor's, suggesting that this AML emerged from donor cells. Additionally, polymorphisms of the XPA, XPD, XRCC1, XRCC3 and RAD51 DNA repair genes revealed three unfavorable alleles with low DNA repair capacity.In summary, we report the first case of AML involving XPD and XRCC3 polymorphisms from donor origin following allogeneic stem cell transplantation and highlight the potential need for careful analysis of DNA repair gene polymorphisms in selecting candidate donors prior to allogeneic stem cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21951951      PMCID: PMC3197559          DOI: 10.1186/1756-8722-4-39

Source DB:  PubMed          Journal:  J Hematol Oncol        ISSN: 1756-8722            Impact factor:   17.388


  35 in total

1.  International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: overview report.

Authors:  Janet D Rowley; Harold J Olney
Journal:  Genes Chromosomes Cancer       Date:  2002-04       Impact factor: 5.006

2.  The stem cell in the pathogenesis and treatment of myelogenous leukemia: a perspective.

Authors:  M A Lichtman
Journal:  Leukemia       Date:  2001-10       Impact factor: 11.528

Review 3.  Polymorphisms in DNA repair genes and associations with cancer risk.

Authors:  Ellen L Goode; Cornelia M Ulrich; John D Potter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-12       Impact factor: 4.254

4.  Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia.

Authors:  J M Allan; C P Wild; S Rollinson; E V Willett; A V Moorman; G J Dovey; P L Roddam; E Roman; R A Cartwright; G J Morgan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

5.  Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/ myelodysplastic syndrome and de novo acute myeloid leukemia.

Authors:  T Naoe; K Takeyama; T Yokozawa; H Kiyoi; M Seto; N Uike; T Ino; A Utsunomiya; A Maruta; I Jin-nai; N Kamada; Y Kubota; H Nakamura; C Shimazaki; S Horiike; Y Kodera; H Saito; R Ueda; J Wiemels; R Ohno
Journal:  Clin Cancer Res       Date:  2000-10       Impact factor: 12.531

6.  Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience.

Authors:  Roy E Smith; John Bryant; Arthur DeCillis; Stewart Anderson
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

7.  XPA polymorphism associated with reduced lung cancer risk and a modulating effect on nucleotide excision repair capacity.

Authors:  Xifeng Wu; Hua Zhao; Qingyi Wei; Christopher I Amos; Kerang Zhang; Zhaozheng Guo; Yawei Qiao; Waun K Hong; Margaret R Spitz
Journal:  Carcinogenesis       Date:  2003-03       Impact factor: 4.944

8.  First report of multiple CEBPA mutations contributing to donor origin of leukemia relapse after allogeneic hematopoietic stem cell transplantation.

Authors:  Haowen Xiao; Jimin Shi; Yi Luo; Yamin Tan; Jingsong He; Wanzhuo Xie; Lifei Zhang; Yingjia Wang; Lizhen Liu; Kangni Wu; Xiaohong Yu; Zhen Cai; Maofang Lin; Xiujin Ye; He Huang
Journal:  Blood       Date:  2011-03-14       Impact factor: 22.113

9.  Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.

Authors:  Michael Crump; Dongsheng Tu; Lois Shepherd; Mark Levine; Vivien Bramwell; Kathleen Pritchard
Journal:  J Clin Oncol       Date:  2003-08-15       Impact factor: 44.544

10.  The genotype distribution of the XRCC1 gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia.

Authors:  Claire Seedhouse; Rowena Bainton; Michael Lewis; Alexander Harding; Nigel Russell; Emma Das-Gupta
Journal:  Blood       Date:  2002-07-18       Impact factor: 22.113

View more
  4 in total

1.  XRCC1 Arg399Gln variation and leukemia susceptibility: evidence from 2,647 cases and 5,518 controls.

Authors:  Yi Huang; Denghai Xie; Nana Tang; Jishi Wang; Xiaoqing Zeng; Peng Zhao; Ling He
Journal:  Tumour Biol       Date:  2013-08-30

Review 2.  Genetics of donor cell leukemia in acute myelogenous leukemia and myelodysplastic syndrome.

Authors:  Lacey Williams; Kimberley Doucette; Judith E Karp; Catherine Lai
Journal:  Bone Marrow Transplant       Date:  2021-03-08       Impact factor: 5.483

Review 3.  Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go.

Authors:  Meng Lv; Xiao-Jun Huang
Journal:  J Hematol Oncol       Date:  2012-03-18       Impact factor: 17.388

4.  Stem cell donors should be screened for CHIP.

Authors:  Amy E DeZern; Lukasz P Gondek
Journal:  Blood Adv       Date:  2020-02-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.